Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 (tecotabart vedotin) in CLDN18.2-Positive Advanced Solid Tumors
NCT05161390Phase 2Completed
- Sponsor
- LaNova Medicines
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tpx-4589 in solid tumor (advanced stage) (2 arms), sponsored by LaNova Medicines. Primary endpoints: Dose limiting toxicity, Adverse Events and Serious Adverse Events and 2 more. Started Nov 2021; status: completed.
02
Drugs
tpx-4589
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05161390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161390.